GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Beneish M-Score

TRAW (Traws Pharma) Beneish M-Score : 108.42 (As of Dec. 13, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 108.42 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Traws Pharma's Beneish M-Score or its related term are showing as below:

TRAW' s Beneish M-Score Range Over the Past 10 Years
Min: -6.9   Med: -2.85   Max: 108.42
Current: 108.42

During the past 13 years, the highest Beneish M-Score of Traws Pharma was 108.42. The lowest was -6.90. And the median was -2.85.


Traws Pharma Beneish M-Score Historical Data

The historical data trend for Traws Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Beneish M-Score Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 -2.87 -2.65 -3.48 -3.36

Traws Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.68 -3.36 -2.84 -1.87 108.42

Competitive Comparison of Traws Pharma's Beneish M-Score

For the Biotechnology subindustry, Traws Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Beneish M-Score falls into.



Traws Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Traws Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 117.8334+0.528 * 1+0.404 * 3.027+0.892 * 1+0.115 * 0.7075
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2072+4.679 * 0.681289-0.327 * 2.611
=108.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $2.12 Mil.
Revenue was 0.057 + 0.057 + 0.056 + 0.056 = $0.23 Mil.
Gross Profit was 0.057 + 0.057 + 0.056 + 0.056 = $0.23 Mil.
Total Current Assets was $8.92 Mil.
Total Assets was $8.94 Mil.
Property, Plant and Equipment(Net PPE) was $0.01 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.01 Mil.
Selling, General, & Admin. Expense(SGA) was $10.90 Mil.
Total Current Liabilities was $8.35 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -8.475 + -123.143 + -4.983 + -4.184 = $-140.79 Mil.
Non Operating Income was 0.061 + -117.259 + 0.229 + 0.278 = $-116.69 Mil.
Cash Flow from Operations was -11.476 + -9.852 + -4.424 + -4.43 = $-30.18 Mil.
Total Receivables was $0.02 Mil.
Revenue was 0.057 + 0.057 + 0.056 + 0.056 = $0.23 Mil.
Gross Profit was 0.057 + 0.057 + 0.056 + 0.056 = $0.23 Mil.
Total Current Assets was $27.01 Mil.
Total Assets was $27.04 Mil.
Property, Plant and Equipment(Net PPE) was $0.03 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.02 Mil.
Selling, General, & Admin. Expense(SGA) was $9.03 Mil.
Total Current Liabilities was $9.67 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.121 / 0.226) / (0.018 / 0.226)
=9.384956 / 0.079646
=117.8334

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.226 / 0.226) / (0.226 / 0.226)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8.923 + 0.012) / 8.936) / (1 - (27.011 + 0.026) / 27.038)
=0.000112 / 3.7E-5
=3.027

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.226 / 0.226
=1

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.016 / (0.016 + 0.026)) / (0.014 / (0.014 + 0.012))
=0.380952 / 0.538462
=0.7075

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10.897 / 0.226) / (9.027 / 0.226)
=48.216814 / 39.942478
=1.2072

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 8.348) / 8.936) / ((0 + 9.674) / 27.038)
=0.934199 / 0.357793
=2.611

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-140.785 - -116.691 - -30.182) / 8.936
=0.681289

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Traws Pharma has a M-score of 108.42 signals that the company is likely to be a manipulator.


Traws Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma Business Description

Traded in Other Exchanges
N/A
Address
12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022